Background: Risk stratification for patients with gastric precancerous lesions for endoscopic surveillance remains controversial.
Aim: To analysis of patients having developed gastric adenocarcinoma during the period of follow-up.
Methods: We conducted a retrospective study on patients having undergone upper endoscopy prior to the development of gastric adenocarcinoma. The presence and stage of precancerous lesions as well as subtype of intestinal metaplasia at the baseline endoscopy got evaluated. Literature mini-review was performed.
Results: Out of 1681 subjects in the Biobank, gastric adenocarcinoma was detected in five cases in whom previous endoscopy data with biopsies either from the corpus or antral part were available. All of the patients had incomplete intestinal metaplasia during the baseline endoscopy; all three subjects in whom intestinal metaplasia subtyping was performed according to Filipe , had Type III intestinal metaplasia. Two of the five cases had low Operative Link on Gastritis Assessment (OLGA) and Operative Link on Gastritis Intestinal Metaplasia Assessment (OLGIM) stages (I-II) at the baseline.
Conclusion: The presence of incomplete intestinal metaplasia, in particular, that of Type III is a better predictor for gastric adenocarcinoma development than OLGA/OLGIM staging system. Subtyping of intestinal metaplasia have an important role in the risk stratification for surveillance decisions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198109 | PMC |
http://dx.doi.org/10.12998/wjcc.v11.i12.2708 | DOI Listing |
J Gastrointest Oncol
December 2024
Department of Gastroenterology, Nanjing Drum Tower Hospital Clinical College of Jiangsu University, Nanjing, China.
Gastric cancer (GC) ranks among the top five most diagnosed cancers globally, with particularly high incidence and mortality rates observed in Asian regions. Despite certain advancements achieved through early screening and treatment strategies in many countries, GC continues to pose a significant public health challenge. Approximately 20% of patients infected with develop precancerous lesions, among which metaplasia is the most critical.
View Article and Find Full Text PDFInt J Biol Macromol
January 2025
Department of Gastrosplenic surgery, Harbin Medical University, Harbin 150000, Heilongjiang Province, China. Electronic address:
Gastric cancer is a prevalent gastrointestinal tumor. In the classical cascade of gastric cancer development, the gradual progression from non-atrophic gastritis, atrophic gastritis, intestinal metaplasia, to intraepithelial neoplasia eventually leads to early gastric cancer. We investigated the proteomic characteristics of chronic gastritis (CG), low-grade intraepithelial neoplasia (low-grade LGIN), and early gastric cancer (EGC).
View Article and Find Full Text PDFCancers (Basel)
January 2025
Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia.
Background/objectives: Gastric intestinal metaplasia (GIM) is considered an irreversible preneoplastic precursor for gastric adenocarcinoma in adults. However, its significance in children and the long-term outcome remain poorly understood.
Methods: All children diagnosed with GIM between 2000 and 2020 were identified at a large tertiary referral centre.
Nutrients
December 2024
Oncological Gastroenterology, Centro di Riferimento Oncologico di Aviano (CRO), National Cancer Institute, IRCCS, 33081 Aviano, Italy.
Background/objectives: Gastric cancer (GC) incidence remains high worldwide, and the survival rate is poor. GC develops from atrophic gastritis (AG), associated with () infection, passing through intestinal metaplasia and dysplasia steps. Since eradication does not exclude GC development, further investigations are needed.
View Article and Find Full Text PDFJ Cancer Prev
December 2024
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Serological tests for needs local validation as the diagnostic accuracy may vary depending on the prevalence of . . This study examined the diagnostic performance of two ELISA, GastroPanel (GastroPanel ELISA; Biohit Oyj) and GENEDIA (GENEDIA .
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!